DOCSLIB.ORG

20 Official Journal of the European Union 23.9.2003

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
20 Official Journal of the European Union 23.9.2003 20EN Official Journal of the European Union 23.9.2003 Appendix referred to in Chapter 1 of Annex VII (*) List as provided by Cyprus in one language of pharmaceutical products for which a marketing authorisation issued under Cypriot law prior to the date of accession shall remain valid until it is renewed in compliance with the acquis or until 31 December 2005, whichever is the earlier. Mention on this list does not prejudge whether or not the pharmaceutical product in question has a marketing authorisation in compliance with the acquis. The attached lists A and B indicate the pharmaceutical products for human use and the veterinary medicinal products respectively, which are currently in circulation in Cyprus. These products were granted their initial marketing author- isation/licence based on the old, non-harmonised legislation. The marketing authorisations of all pharmaceutical products listed, will be renewed (if requested by the manufacturers and/or importers) during 2004 and 2005 in accordance with the provisions of the new, harmonised legislation and eventually, fully harmonised dossiers will be achieved by 31 December 2005. LIST A: MEDICINAL PRODUCTS FOR HUMAN USE Code No Product 9900231 4-WAY NASAL FAST ACTING SPRAY 1% 9800571 5-FLUOROURACIL ‘EBEWE’ VIALS 50MG/ML, 10ML 9800570 5-FLUOROURACIL ‘EBEWE’ VIALS 50MG/ML, 5ML 9700037 -5-FLUOROURACIL INJECTION 50MG/ML 9800572 5-FLUOROURACIL‘EBEWE’ VIALS 50MG/ML, 20ML 20050619 99F0165 HAIR & NAILCARE CAPSULES 97F0150 ABC SPEKTRUM TABLETS 9800252 ABERNIL TABLETS 50MG 9800252 ABERNIL TABLETS 50MG 9800550 AB-HYOSCINE BUTYLBROMIDE INJECTION 20MG/ML 9900615 ACARILBIAL LIQUID 8700493 ACEPROTIN TABLETS 25MG 8700492 ACEPROTIN TABLETS 50MG 97F0154 ACEROLA TABLETS 500MG 9700217 ACETAZOLAMIDE TABLETS 250MG 9400248 ACETAZONE FORTE TABLETS 9500684 ACICLOVIR GOLGI CREAM 5% W/W 99F0042 ACIDOPHILUS CAPSULES 40MG 9500658 ACIDRINE TABLETS 8400119 ACTIFED DM COUGH LINCTUS SYRUP 8200220 ACTIFED EXPECTORANT SYRUP 8100193 ACTIFED TABLETS 9800445 ACTIVELLE TABLETS 8900382 ACTRAPID HM INJECTION 100IU/ML, 10ML VIALS 9400342 ACTRAPID HM PENFILL INJECTION 100IU/ML, 3ML CARTR 8900381 ACTRAPID HM PENFILL INJECTION 100IU/ML,1.5ML CARTR 8500351 ACTRAPID MC INJECTION 100IU/ML, 10ML VIALS 9500243 ACUITEL FILM COATED TABLETS 10MG 9000392 ACUITEL FILM COATED TABLETS 20MG 9000391 ACUITEL FILM COATED TABLETS 5MG (*) For the text of Annex VII see OJ L 236, 23.9.2003, p. 819. 23.9.2003EN Official Journal of the European Union 21 Code No Product 9900565 ACYCLOVIR TABLETS 200MG 9900566 ACYCLOVIR TABLETS 400MG 9900567 ACYCLOVIR TABLETS 800MG 9900222 ADAFERIN GEL 0.1% 9600391 ADALAT CC COATED TABLETS 30MG 2000367 ADALAT LA TABLETS 30MG 2000368 ADALAT LA TABLETS 60MG 8600670 ADALAT RETARD SUSTAINED RELEASE TABLETS 20MG 8400620 ADD-ACTEN TABLETS 9800269 ADDITIVA CALCIUM EFFERVESCENT TABLETS 500MG 9800270 ADDITIVA ETSEN (Fe2+) EFFERVESCENT TABLETS 18MG 9800267 ADDITIVA MAGNESIUM EFFERVESCENT TABLETS 150MG 9500062 ADDITIVA VITAMIN C BLUTORANGE EFFERVESCENT TABLETS 9400204 ADENOCOR IV INJECTION 6MG/2ML 9600520 ADENOSAN SHAMPOO 2% 9900497 AD-MUC OINTMENT 9600447 ADVANTAN CREAM 1MG 9600446 ADVANTAN FATTY OINTMENT 1MG 9600448 ADVANTAN OINTMENT 1MG 9800554 ADVIL SUGAR COATED TABLETS 200MG 9900665 AGELMIN FILM COATED TABLETS 10MG 8000431 A-GEN VAGINAL SUPPOSITORIES 9800604 AGGRASTAT IV CONCENTRATE FOR INFUSION 0.25MG/ML 9400018 AGRIPPAL S1 INJECTION 0.5ML 9600519 AIDOL ORAL SUSP. 50MG/5ML 9200363 AIDOL TABLETS 500MG 9200138 AIRTAL TABLETS 100MG 8700541 AKAMON TABLETS 1.5MG 7900048 AKINETON RETARD SUSTAINED RELEASE TABLETS 4MG 7900047 AKINETON TABLETS 2MG 9700548 AKNE-MYCIN EMULSION 1% 9700546 AKNE-MYCIN OINTMENT 2% 9700544 AKNE-MYCIN SOLUTION 2% 9700553 AKNEROXID GEL 5% 8400033 AKTIFERRIN-F SOFT GELATIN CAPSULES 9800454 ALBUMIN HUMAN INFUSION 20% 2000082 ALBUMIN HUMAN INFUSION 20%, 100ML 2000081 ALBUMIN HUMAN INFUSION 20%, 50ML 9900663 ALCITON NASAL SPRAY 0.02% 8900771 ALDACTONE TABLETS 100MG 8900778 ALDACTONE TABLETS 25MG 7700404 ALDIX TABLETS 40MG 9400497 ALFINOR TABLETS 8MG 22EN Official Journal of the European Union 23.9.2003 Code No Product 9400351 ALFOXAN SYRUP 50MG/5ML 9600192 ALGAMEX CHEWABLE TABLETS 500MG 9500549 ALGESALONA CREAM 9500021 ALGIDOL SACHETS 2000146 ALLERGODIL EYE DROPS 0.05% 9400066 ALLERGODIL NASAL SPRAY 0.1% W/V 9600190 ALLERGOTIN EYE DROPS 2% 9600191 ALLERGOTIN EYE DROPS 4% 95F0507 ALLITHERA CAPSULES 500MG 8500222 ALLOPURINOL-RATIOPHARM TABLETS 300MG 9400303 ALLVORAN FILM COATED TABLETS 25MG 9400304 ALLVORAN FILM COATED TABLETS 50MG 9400305 ALLVORAN RETARD SUSTAINED RELEASE TABLETS 100MG 9400306 ALLVORAN S SUPPOSITORIES 100MG 9400307 ALLVORAN SF INJECTION 75MG/3ML 8400703 ALMIRAL ENTERIC COATED TABLETS 25MG 8400704 ALMIRAL ENTERIC COATED TABLETS 50MG 8900321 ALMIRAL GEL 1% W/W 9000030 ALMIRAL INJECTION 25MG/ML, 3ML 8500461 ALMIRAL SUSTAINED RELEASE TABLETS 100MG 9700190 ALOMIDE EYE DROPS 0.1% W/V 9900064 ALPHAGAN EYE DROPS 0.2% 8500121 ALPHOSYL CREAM 8500123 ALPHOSYL HC CREAM 9900568 ALPRAZOLAM TABLETS 0.25MG 9500538 ALPRAZOLAM TABLETS 0.5MG 9900569 ALPRAZOLAM TABLETS 0.5MG 9500539 ALPRAZOLAM TABLETS 1MG 9900570 ALPRAZOLAM TABLETS 1MG 9000272 ALTEN CREAM 0.05% 9000574 ALUTRIL CHEWABLE TABLETS 9300401 ALVEOFACT VIALS 8400625 ALVERIX TABLETS 5MG 9500657 ALVITYL SYRUP 7500071 ALVOGYL PASTE 9800083 AMARIN CAPSULES 15MG 9800083 AMARIN CAPSULES 15MG 9300372 AMARIN CAPSULES 30MG 9600437 AMARYL TABLETS 1MG 9600438 AMARYL TABLETS 2MG 9600439 AMARYL TABLETS 3MG 8700532 AMBEN POWDER FOR ORAL SUSP. 250MG/5ML 8700533 AMBEN POWDER FOR ORAL SUSP. 500MG/5ML 23.9.2003EN Official Journal of the European Union 23 Code No Product 9500046 AMBROHEXAL TABLETS 30MG 8800617 AMBROXOL-RATIOPHARM SUSTAINED RELEASE CAPSULES 75MG 8200373 AMEN TABLETS 100MG 8600268 AMILORID COMP TABLETS 8400311 AMILORIDE TABLETS 5MG 9800314 AMILOZID-B TABLETS 8600091 AMINOPHYLLINE SUPPOSITORIES 360MG 9200111 AMINOPHYLLINE TABLETS 250MG 7600433 AMINOPLASMAL L-10 PARENTERAL SOLUTION 500ML 7600432 AMINOPLASMAL L-5 PARENTERAL SOLUTION 500ML 9700201 AMINOSTERIL INFUSION 10% 8300489 AMIODARONE TABLETS 200MG 8000536 AMIROL FILM COATED TABLETS 10MG 8000573 AMIROL FILM COATED TABLETS 25MG 9900443 AMITRIPTYLINE HCI TABLETS 10MG 9900444 AMITRIPTYLINE HCI TABLETS 25MG 9900445 AMITRIPTYLINE HCI TABLETS 50MG 9400453 AMODEX CAPSULES 500MG 9400455 AMODEX POWDER FOR RECONSTITUTION 250MG/5ML 9400456 AMODEX POWDER FOR RECONSTITUTION 500MG/5ML 9100074 AMODIAQUINE FILM COATED TABLETS 200MG 8100069 AMOXAPEN CAPSULES 250MG 9000233 AMOXICILLIN-RATIOPHARM 250TS POWDER FOR ORAL SUSP. 250MG/5ML 8900146 AMOXICILLIN-RATIOPHARM 500 FILM COATED TABLETS 500MG 7201303 AMOXIL CAPSULES 250MG 7201306 AMOXIL FORTE POWDER FOR ORAL SUSP. 250MG/5ML 7201304 AMOXIL PAEDIATRIC DROPS 100MG/ML 7700299 AMOXIL POWDER FOR INJECTION 250MG VIALS 7700300 AMOXIL POWDER FOR INJECTION 500MG VIALS 7201305 AMOXIL POWDER FOR ORAL SUSP. 125MG/5ML 9000114 AMOXIMEX POWDER FOR ORAL SUSP. 250MG/5ML 9000116 AMOXIMEX TABLETS 1000MG 9000115 AMOXIMEX TABLETS 500MG 9000209 AMOXY-DIOLAN POWDER FOR ORAL SUSPENSION 250MG/5ML 9100186 AMPICILLIN-VOGEN CAPSULES 500MG 9300414 AMPISUL CAPSULES 250MG 9300415 AMPISUL CAPSULES 500MG 9500534 AMYZOL CAPSULES 50MG 2000188 ANABACT GEL 0.75% W/W 8800463 ANADIN TABLETS 500MG 9900358 ANAFRANIL INJECTION 25MG/2ML 9900372 ANAFRANIL SLOW RELEASE TABLETS DIVIDABLE 75MG 9900357 ANAFRANIL SUGAR COATED TABLETS 10MG 24EN Official Journal of the European Union 23.9.2003 Code No Product 9900356 ANAFRANIL SUGAR COATED TABLETS 25MG 8500298 ANALGISER TABLETS 500MG 9300396 ANAVIX SYRUP 15MG/5ML 9300397 ANAVIX SYRUP 30MG/5ML 8400083 ANDRIOL CAPSULES 40MG 8300175 ANDROCUR TABLETS 10MG 8300176 ANDROCUR TABLETS 50MG 7100385 ANERVAN SUPPOSITORIES 7100384 ANERVAN TABLETS 9400085 ANFADOX CAPSULES 100MG 9900164 ANGINOVA TABLETS 2000046 ANTHISAN PLUS SPRAY 9800331 ANTIBIOPTAL EYE DROPS 9400290 ANTIFUNGOL CREAM 1% 8900553 ANTIKINAL TABLETS 5MG 2100049 ANTIPHLOGISTINE RUB A-535 CAPSAICIN GEL 2100048 ANTIPHLOGISTINE RUB A-535 EXTRA-STRENGTH OINTMENT 2100050 ANTIPHLOGISTINE RUB A-535 HEAT OINTMENT 2100047 ANTIPHLOGISTINE RUB A-535 ICE GEL 4% W/W 9400216 ANTISPASMINA COLICA FORTE TABLETS 8000418 ANTISTIN-PRIVIN EYE DROPS 7300136 ANUSOL OINTMENT 9500180 ANZATAX CONCENTRATE INJECTION 6MG/ML, 5ML 9500181 ANZATAX CONCENTRATE INJECTION 6MG/ML, 5ML VIAL 9700136 APONIL TABLETS 100MG 9900284 APRESOLINE' FILM COATED TABLETS 25MG 9900283 APRESOLINE SUGAR COATED TABLETS 10MG 8000260 APROXAL CAPSULES 500MG 8000262 APROXAL POWDER FOR ORAL SUSP. 250MG/5ML 8000261 APROXAL POWDER FOR ORAL SUSPENSION 125MG/5ML 8200038 APROXAL POWDER FOR ORAL SUSPENSION 500MG/5ML 8400312 ARBAT FILM COATED TABLETS 200MG 8400313 ARBAT FILM COATED TABLETS 400MG 9900393 AREDIA POWDER FOR INJECTION 60MG WITH SOLVENT 9900392 AREDIA VIALS POWDER FOR INJECTION 90MG 9900522 ARESTON TABLETS 50MG 9400519 ARFAREL SOLUTION 10MG/ML 9800560 ARFEN PLUS TABLETS 500/50MG 9800560 ARFEN PLUS TABLETS 500/50MG 8400422 ARFEN SUSP. 120MG/5ML 9800605 ARFEN TABLETS 100MG 7700497 ARFEN TABLETS 500MG 23.9.2003EN Official Journal of the European Union 25 Code No Product 9600413 ARIMIDEX TABLETS 1MG 9800343 ARNETIN INJECTION 25MG/ML 9200036 ARNETIN TABLETS 150MG 2000480 ARNETIN TABLETS 300MG 9900526 AROMASIN SUGAR COATED TABLETS 25MG 8600580 ARPHOS VITAMIN B12 AMPOULES DRINKABLE 9000465 ARTHRINAL FILM COATED TABLETS 20MG 9700291 ARTHROTEC 75 TABLETS 9500087 ARTHROXEN TABLETS 250MG 9500088 ARTHROXEN TABLETS 500MG 8700174 ASACOL FILM COATED TABLETS 400MG 9400466 ASPEGIC 100 FOR CHILDREN AND INFANTS PDR 180MG IN SACHETS 9400465 ASPEGIC 1000 POWDER 1800MG IN SACHETS 9400463
Load more

Recommended publications
  • Lipid-Based Depots: Manufacturing, Administration and Interactions of Protein Drugs with Lipid Formulations
    Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München Lipid-based depots: manufacturing, administration and interactions of protein drugs with lipid formulations Michaela Maria Breitsamer aus Starnberg, Deutschland 2019 II ERKLÄRUNG Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von Herrn Prof. Dr. Gerhard Winter betreut. EIDESSTATTLICHE VERSICHERUNG Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet. Wolfratshausen, den 20.05.2019 ________________________________ (Michaela Breitsamer) Dissertation eingereicht am: 20.05.2019 1. Gutachter: Prof. Dr. Gerhard Winter 2. Gutachter: Prof. Dr. Wolfgang Frieß Mündliche Prüfung am: 25.06.2019 III IV FOR MY FAMILY “The way to get started is to quit talking and begin doing” Walt Disney (1901 – 1966) V VI ACKNOWLEDGEMENTS The present thesis was prepared between March 2015 and December 2018 at the Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics at the Ludwig-Maximilians Universität (LMU) in Munich under the supervision of Prof. Dr. Gerhard Winter. First of all, I would like to express my deepest gratitude to my supervisor Prof. Dr. Gerhard Winter for giving me the opportunity to join his research group and to work on this extremely interesting and interdisciplinary project. I really appreciated his scientific input throughout all phases of this work, his elaborate advice and his guidance, which also contributed to my personal development over the last years. Furthermore, I would like to thank him for the outstanding working and team atmosphere, which he created at the chair, for supporting my participation in scientific conferences and for initiating and motivating me to the numerous collaborations which contributed to a successful thesis.
    [Show full text]
  • Food and Drugs Regulations
    LAWS OF TRINIDAD AND TOBAGO 22 Chap. 30:01 Food and Drugs SUBSIDIARY LEGISLATION FOOD AND DRUGS REGULATIONS ARRANGEMENT OF REGULATIONS REGULATION 1. Citation. 2. Requirements prescribed by regulation. 3. Interpretation. 4. Request to Director. 5. Functions, duties, responsibilities of Inspectors. 6. Certificate of appointment. 7. Taking of photographs. 8. Taking samples and detention pending further examination. 9. Violation of Act or Regulations and relabelling or recondition­ ing of food, drug, cosmetic or device. 10. Issue of certificate. 11. Taking a sample, notification of intention and division of sample. 12. Division an interference and objection to procedure by owner or person. 13. Certificate of Analysis. 14. Definition of terms in Part II. 15. Offence to sell unlabelled food. 16. Labelling of package. 17. Declaration of net contents not required on certain labels. 18. List of ingredients not required on certain labels. 19. Declaration not required. 20. Declaration not required to indicate presence of flavouring. 21. Dried or dehydrated products. 22. Food from vending machine. 23. Non application of regulation 16. 24. Standard for a food. 25. Name of designation given to standard, grade or definition. 26. Adulteration of food. 27. Non-adulteration. 28. Contents of package. 29. Display of information on label. 30. First Schedule. 31. Offence. 32. Definition of terms in Part III. 33. Labelling of drug. 34. Contents of label. 35. Label on bulk package. 36. Drug sold on prescription. 37. Packing cases. LAWS OF TRINIDAD AND TOBAGO Food and Drugs Chap. 30:01 23 Food and Drugs Regulations [Subsidiary} REGULATION 38. Name and proportion of drug to be stated on label.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrFLUANXOL® Flupentixol Tablets (as flupentixol dihydrochloride) 0.5 mg, 3 mg, and 5 mg PrFLUANXOL® DEPOT Flupentixol Decanoate Intramuscular Injection 2% and 10% flupentixol decanoate Antipsychotic Agent Lundbeck Canada Inc. Date of Revision: 2600 Alfred-Nobel December 12th, 2017 Suite 400 St-Laurent, QC H4S 0A9 Submission Control No : 209135 Page 1 of 35 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................21
    [Show full text]
  • Depot Antipsychotic Injections
    Mental Health Services Good Practice Statement For The Use Of DEPOT & LONG ACTING ANTIPSYCHOTIC INJECTIONS Date of Revision: February 2020 Approved by: Mental Health Prescribing Management Group Review Date: CONSULTATION The document was sent to Community Mental Health teams, Pharmacy and the Psychiatric Advisory Committee for comments prior to completion. KEY DOCUMENTS When reading this policy please consult the NHS Consent Policy when considering any aspect of consent National Institute for Clinical Excellence CG178 (2014), Psychosis and schizophrenia in adults: prevention and management NHS Lothian (2011), Depot Antipsychotic Guidance, Maudsley (2015), Prescribing Guidelines in Psychiatry 12th edition. UKPPG (2009) Guidance on the Administration to Adults of Oil based Depot and other Long Acting Intramuscular Antipsychotic Injections Summary of Product Characteristics for: Clopixol (Zuclopethixol Decanoate) Flupenthixol Decanoate Haldol (Haloperidol Decanoate) Risperdal Consta Xeplion (Paliperidone Palmitate) ZypAdhera (Olanzapine Embonate) Abilify Maintena (Aripiprazole) 1 CONTENTS REFERENCES/KEY DOCUMENTS …………………………………………………………… 1 INTRODUCTION …………………………………………………………………………………. 3 SCOPE …………………………………………………………………………………………….. 3 DEFINITIONS ……………………………………………………………………………………... 3 CHOICE OF DRUG AND DOSAGE SELECTION ……………………………………………. 3 SIDE EFFECTS ……………………………………………………………….………………….. 5 PRESCRIBING …………………………………………………………………………………… 5 ADMINISTRATION ………………………………………………………………………………. 7 RECORDING ADMINISTRATION ……………………………………………………………… 7
    [Show full text]
  • North of England Guidance for Long Acting Antipsychotic Injections July 17
    Guidance on the Use of Antipsychotic Long-acting Injections in North of England (TEWV version) This guidance aims to inform and support prescribers within the three mental health service providers in the north of England in the cost-effective use of antipsychotic long-acting injections. Long-acting or “depot” injections are a useful and well-established form of administering antipsychotics in the management of schizophrenia and other psychoses. The introduction of long-acting formulations of second-generation (atypical) antipsychotics has created an additional pressure on drug budgets in mental health services, which may be justified if their use results in reduced hospital admissions, shortened length of stay and improved quality of life compared with the first generation (typical) agents. Advantages of long-acting / depot injections Assured compliance with antipsychotic treatment Increased bioavailability (less first-pass metabolism) Steady plasma levels compared to oral medication Reduction in relapse rate, severity of relapse and rehospitalisation Stable therapeutic effects Better downward titration to minimise side-effects There is some evidence that long-acting injections cause less brain tissue loss and deterioration (CATIE study1) Disadvantages of long-acting / depot injections Treatment cannot be stopped quickly if severe side-effects develop (dystonia, EPSE, NMS) Perception by the patient of “being controlled”, losing control over their treatment, or possibly being punished. Pain at the site of injection, lasting possibly 10 days Tissue necrosis - over time hard plaques may form, which will reduce the ease of administration and the efficacy of the injection as well as causing discomfort. Loss of dignity with the gluteal route Over and above these factors, NICE2 recommend that consideration should be given to offering a depot / long-acting injectable antipsychotic to people with psychosis or schizophrenia who express a preference for such treatment after an acute episode.
    [Show full text]
  • Formulary Update
    PEI Drug Programs Formulary Update Issue 06-04 October, 2006 The following changes and additions to the July 2006 edition of the PEI Drug Programs Formulary will be effective October 16th, 2006 unless otherwise noted within this update. If there are any questions regarding the information presented in this update please call the Drug Program office at 368-4947 or toll free at 1-877-577-3737. 1.0 Changes and Additions To The Formulary & MAC Pricing ALMOTRIPTAN (new addition) EDS Criteria: For the treatment of migraine headaches where other standard therapies, such as analgesics and/or ergotamine products have failed. Eligibility is restricted to persons over the age of 18 and under 65 years of age. Coverage is limited to 6 tablets per 30 day period. Persons requiring more than 6 doses per 30 day period should be considered for migraine prophylaxis therapy if they are not already receiving such therapy. 6.25mg tablet 02248128 AXERT (EDS) JAN FW 12.5mg tablet 02248129 AXERT (EDS) JAN FW DILTIAZEM HYDROCHLORIDE (new addition) 120mg capsule 02231150 TIAZAC BVL FNSW 180mg capsule 02231151 TIAZAC BVL FNSW 240mg capsule 02231152 TIAZAC BVL FNSW 300mg capsule 02231154 TIAZAC BVL FNSW 360mg capsule 02231155 TIAZAC BVL FNSW PEI Drug Programs Formulary Update Issue 06-04 October 2006 Page 1 DILTIAZEM HYDROCHLORIDE (new addition) 120mg extended release tablet 02256738 TIAZAC XC BVL FNSW 180mg extended release tablet 02256746 TIAZAC XC BVL FNSW 240mg extended release tablet 02256754 TIAZAC XC BVL FNSW 300mg extended release tablet 02256762 TIAZAC XC BVL FNSW 360mg extended release tablet 02256770 TIAZAC XC BVL FNSW ETHINYL ESTRADIOL/DROSPIRENONE (new addition) 3.0mg/0.03mg tablets 02261723 YASMIN 21 DAY BEX FW 02261731 YASMIN 28 DAY BEX FW ESPROSARTAN MESYLATE & HYDROCHLOROTHIAZIDE (new addition) 600mg & 12.5mg tablet 02253631 TEVETEN PLUS SLV FNSW GABAPENTIN (change) There is no longer an EDS restriction on this drug.
    [Show full text]
  • Regencerx Preferred Medication List/Formulary Regencerx Preferred Effective February 1, 2008 ©2008
    RegenceRx Preferred Medication List/Formulary Help to stretch your prescription dollar February1, 2008 ©2008. RegenceRx. All Rights Reserved. ©2008. RegenceRx. Effective February 1,2008 Effective 2 Your Preferred Medication List/Formulary 3 Common Questions and Answers Preferred/Formulary Medications 4-11 • By Category • A to Z Listing 12-17 – Generics 18-22 – Preferred/Formulary Brands Non-Preferred/Non-Formulary Brands 23-27 • Generic and Preferred Brand Alternatives Table of Contents Table Effective February 1, 2008 ©2008. RegenceRx. All Rights Reserved. RegenceRx is dedicated to provide the tools you need to understand your options and be a more informed consumer. This preferred medication list/formulary will help—with the answers you need to access affordable prescription benefits. Determining Cost Newly-introduced How much you pay for a prescription generic medications depends on whether it’s a: When a generic is introduced to the • Generic marketplace, it immediately becomes • Preferred/formulary brand name available at the lowest copay. After a • Non-preferred/non-formulary generic is available, the brand name brand name (brand name medication will only be available at the medication not on the list) non-preferred/non-formulary copay. Your cost is lowest for generic Preferred/formulary medications and highest for non- brand name medications preferred/non-formulary brand name Brand name medications on the medications. You can find specific preferred medication list (PML) coverage and copay information in have been chosen because our your summary of benefits. professional review has shown each Generic medications of them to be high-quality, effective, Generics provide the same and affordable. Preferred/formulary therapeutic benefits of their brand brand name medications are either name counterparts, without the more effective or equally effective—at brand name price.
    [Show full text]
  • 2019 Careoregon Advantage Plus Comprehensive Formulary
    2019 CareOregon Advantage Customer Service CALL: 503-416-4279 or toll-free 888-712-3258 Drug List (Formulary) TTY/TDD: 711 HOURS OF OPERATION: every day, 8 a.m. to 8 p.m. CareOregon Advantage Plus (HMO-POS SNP) For Oregon counties: Clackamas, Columbia, Jackson, Multnomah, Tillamook and Washington facebook.com/careoregon twitter.com/careoregon careoregonadvantage.org H5859_PH2019_1085_C CMS ACCEPTED COA-18422.05-0820 CareOregon Advantage Plus HMO-POS SNP 2019 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN H5859_PH2019_1085_C FORMULARY ID 00019571, VERSION 27 This formulary was updated on December 1, 2019. For more recent information or other questions, please contact CareOregon Advantage Customer Service at 888-712-3258 or, for TTY/TDD users, 711, 8 a.m. to 8 p.m., daily, or visit careoregonadvantage.org Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Health Plan of CareOregon, Inc. When it refers to “plan” or “our plan,” it means CareOregon Advantage Plus. This document includes a list of the drugs (formulary) for our plan which is current as of December 1, 2019. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2020, and from time to time during the year.
    [Show full text]
  • Review of Painless Injection Technology Pooja A
    International Journal of Innovative and Emerging Research in Engineering Volume 2, Issue 9, 2015 Available online at www.ijiere.com International Journal of Innovative and Emerging Research in Engineering e-ISSN: 2394 - 3343 p-ISSN: 2394 - 5494 Review of Painless Injection Technology a b Pooja A. Kshirsagar , Abhijit G. Kalbande a Student- Pooja A. Kshirsagar, PRMCEAM, Bandera, Amravati, Maharashtra b Lecturer - Abhijit G.Kalbande, PRMCEAM, Bandera, Amravati, Maharashtra ABSTRACT: The Painless Injection Technology play the important role in our life because in our country we have seen the so many people who are having a phobia for giving an injection which has a needle, that’s why in Painless Injection Technology we used the needle free injection. This painless injection has the electronic circuit for making injection devices. Today, this is a very rising technology that avoids the pain and infection having needle based injection. This painless injection technology is very easiest way to delivering the vaccines into skin. Keywords: Needle Free,Injection,Phobia,Technology,Vaccine,Drug I. INTRODUCTION Since 150 years we have seen the needle based injection for giving an injection into the skin. They form the major part of perenteral dosage form [1, 2]. To overcome problems related to needle based injection there is one technology that has received constant attention during the past few years that has all of the sought after benefits i.e. Needle free injection. The needle free injection don’t have needle but make use of electronic circuit to drive drugs through skin. These needle free injections are available in the form of power sprays, edible products, Inhaler’s and skin patches [1, 3].
    [Show full text]
  • 202971Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 202971Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) NDA202971 Aripiprazole IM Depot Formulation Clinical Pharmacology Review NDA #: 202,971 Proposed Brand Name: ABILIFY MAINTENA Generic Name: Aripiprazole Dosage Form: IM Depot (Extended-Release Suspension for IM Injection) Dosage Strength: 300-mg Vial, 400-mg Vial Indication: Maintenance Treatment of Schizophrenia Sponsor: Otsuka Submission Type: 505(b)(1) Submission Date: Sep. 26, 2011 Huixia Zhang, Satjit Brar, Mike Pacanowski, Atul Bhattaram, OCP Review Team: Hao Zhu OCP Required Inter-Division Briefing was held on May 14, 2012. Table of Contents 1. Executive Summary......................................................................................................... 3 1.1. Recommendation ........................................................................................................... 3 1.1.1. Labeling Recommendations .......................................................................................... 3 1 Indications and Usage...................................................................................................... 3 2.3 Dosage Adjustments for Dosage Adjustments for Missed Doses ......................................... 4 1.2. Phase IV Requirements/Commitments .......................................................................... 4 1.3. Summary of Clinical Pharmacology Findings.............................................................. 4 2. Question Based Review ..................................................................................................
    [Show full text]
  • Needle-Free Drug Delivery Technology
    Drug Delivery & Formulation Needle-Free Drug Delivery Technology The needle-free industry now has a broad range of excellent technology to meet customer needs; the only remaining barrier lies with the pharmaceutical and biotechnology companies themselves. By Dr Roger G Harrison, Consultant to Antares Pharma, Inc Dr Roger G Harrison has been a Consultant to Antares Pharma since September 2004. Prior to that he had been the Chief Executive officer, President and member of the Board of the Company since March 2001. Previous to that, he held various positions at Eli Lilly and Company for more than 25 years, with his most recent role being Director of Alliance Management from May 1999 until February 2001. Other positions at Eli Lilly included Global Product Team Leader, Director, Development Projects Management and Technology Development and Planning, and Director of Biochemistry Research. He is the author of numerous publications, has contributed to four books and holds nine patents. Dr Harrison earned a PhD in Organic Chemistry and a BSc in Chemistry from Leeds University in the UK and conducted postdoctoral research work at Zurich University in Switzerland. All parents can relate to the anguish felt when an infant players now compete on the relative sophistication screams and protests at the sight of a vaccination of their delivery technology. If pundits are to be needle. Later in life, the screams may abate but believed, the next innovation in this sector will significant misgivings usually still exist about the be pulmonary inhalation, which is being developed insertion of a needle for delivery of vaccines or (at very significant cost) by Pfizer, Lilly and therapeutic agents, with relief when the process is over.
    [Show full text]
  • Investigation of Depot Neuroleptic Injection Site Reactions
    ORIGINAL PAPERS Investigation of depot neuroleptic injection site reactions Julie C. Jones, Jennifer C. Day, John R. Taylor and Christophers. Thomas Aims and method A cross-sectional survey was ship between reactions and other related vari performed on 318 patients receiving depot ables such as dose, volume, concentration and medication. The presence or absence of a depot site frequency of injection, age, gender and body reaction was recorded by psychiatric nursing staff on a mass index. All patients prescribed depot standardised form. neuroleptic medication attending the depot clinic Results Seventeen per cent of patients were found to at Withington Hospital in south Manchester and have clinically significant depot site reactions. Such from a defined catchment area of south Liverpool reactions were associated with increased frequency of were included in the study. All patients who injection and increased total volume of depot participated gave informed consent, and the administered in the previous 12 months. The severity of study was approved by the local ethics commit a depot site reaction was unrelated to the tees. The following demographic and clinical concentration of depot preparation administered. details were recorded: age, gender, case note Clinical implications Depot site reactions may be diagnosis, date of first episode, dose and reduced by maximising the interval between frequency of depot and all other current medic injections and using low volume (highly concentrated) ation. Details relating to depot administration preparations of depot neuroleptic medication. were systematically collected on a standard form (available from the author upon request), includ ing the volume of depot administered at the time The use of depot neuroleptics in patients suffer of survey, total volume of depot administered in ing from schizophrenia has been associated with the previous year, total number of injections improved compliance and reduced rates of administered in the previous year and any relapse (Hirsch et al 1973; Gottfries & Green.
    [Show full text]